| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6586 | 2016 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3678 | 2016 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2069 | 2017 |
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C B Sangro, C Gomez-Martin, M de la Mata, M Iñarrairaegui, E Garralda, ... Journal of hepatology 59 (1), 81-88, 2013 | 1024 | 2013 |
| Cytokines in clinical cancer immunotherapy P Berraondo, MF Sanmamed, MC Ochoa, I Etxeberria, MA Aznar, ... British journal of cancer 120 (1), 6-15, 2019 | 947 | 2019 |
| Evolving synergistic combinations of targeted immunotherapies to combat cancer I Melero, DM Berman, MA Aznar, AJ Korman, JL Perez-Gracia, J Haanen Nature Reviews Cancer 15 (8), 457-472, 2015 | 709 | 2015 |
| Direct effects of type I interferons on cells of the immune system S Hervas-Stubbs, JL Perez-Gracia, A Rouzaut, MF Sanmamed, A Le Bon, ... Clinical Cancer Research 17 (9), 2619-2627, 2011 | 626 | 2011 |
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma KA Schalper, ME Rodriguez-Ruiz, R Diez-Valle, A López-Janeiro, ... Nature medicine 25 (3), 470-476, 2019 | 532 | 2019 |
| CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ... Immunity 52 (5), 856-871. e8, 2020 | 467 | 2020 |
| Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients MF Sanmamed, JL Perez-Gracia, KA Schalper, JP Fusco, A Gonzalez, ... Annals of Oncology 28 (8), 1988-1995, 2017 | 393 | 2017 |
| Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs) C Alfaro, A Teijeira, C Oñate, G Perez, MF Sanmamed, MP Andueza, ... Clinical Cancer Research 22 (15), 3924-3936, 2016 | 362 | 2016 |
| Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ... Nature 569 (7756), 428-432, 2019 | 356 | 2019 |
| Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors KA Schalper, M Carleton, M Zhou, T Chen, Y Feng, SP Huang, AM Walsh, ... Nature medicine 26 (5), 688-692, 2020 | 342 | 2020 |
| Interleukin-8 in cancer pathogenesis, treatment and follow-up C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz, Á Teijeira, C Oñate, ... Cancer treatment reviews 60, 24-31, 2017 | 317 | 2017 |
| Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma TK Choueiri, MN Fishman, B Escudier, DF McDermott, CG Drake, ... Clinical Cancer Research 22 (22), 5461-5471, 2016 | 277 | 2016 |
| Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with … MF Sanmamed, S Fernández-Landázuri, C Rodríguez, R Zárate, ... Clinical chemistry 61 (1), 297-304, 2015 | 274 | 2015 |
| Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy AR Sánchez-Paulete, A Teijeira, FJ Cueto, S Garasa, JL Pérez-Gracia, ... Annals of Oncology 28, xii44-xii55, 2017 | 259 | 2017 |
| Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ... Clinical Cancer Research 25 (15), 4663-4673, 2019 | 256 | 2019 |
| Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS MF Sanmamed, F Pastor, A Rodriguez, JL Perez-Gracia, ... Seminars in oncology 42 (4), 640-655, 2015 | 255 | 2015 |
| Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins MF Sanmamed, O Carranza-Rua, C Alfaro, C Onate, S Martín-Algarra, ... Clinical Cancer Research 20 (22), 5697-5707, 2014 | 239 | 2014 |
